title: Intravenous bisphosphonate-related osteonecrosis of the jaws: influence of coadjuvant antineoplastic treatment and study of buccodental condition.
abstract: OBJECTIVE
  To determine whether coadjuvant antineoplastic treatment can influence the number and size of bone exposures among patients with intravenous bisphosphonate-related osteonecrosis of the jaws (iBRONJ), and to analyze the buccodental condition of these patients.
  
  
  METHODS
  The study sample comprised 67 patients with iBRONJ, 53 patients without iBRONJ receiving treatment with intravenous bisphosphonates, and 36 healthy subjects. In all three groups, measurements were made of the CAO index and of resting whole saliva and stimulated whole saliva. In the patients with iBRONJ, the size (cm) and number of bone exposures were recorded. The data obtained were subjected to analysis of variance (ANOVA), the Mann-Whitney U-test, and multivariate logistic regression analysis.
  
  
  RESULTS
  A total of 57.6% of the patients presented single bone exposure, 25.4% presented two, and 17% more than two exposures. The mean exposure size was 2.3 ± 1.9 cm. Neither the bivariate analysis nor the multivariate multiple regression analysis found coadjuvant antineoplastic treatment to exert a statistically significant effect upon the number and size of bone exposures. On the other hand, there were statistically significant differences among the three study groups in relation to the CAO index (p=0.02) and the number of missing teeth (p=0.00). The resting whole saliva and stimulated whole saliva levels were similar in the three groups, though the patients with osteonecrosis of the jaws showed comparatively lower SWS levels.
  
  
  CONCLUSIONS
  Coadjuvant antineoplastic treatment alone appears to exert no influence upon the size and number of bone exposures in iBRONJ. The patients with this disease show a higher CAO index and a larger number of missing teeth.
authors.affiliation: Oral Medicine Unit, Department of Stomatology, University of Valencia,Valencia, Spain. maria.margaix@uv.es
authors.forename: Maria
authors.initials: M
authors.lastname: Margaix-Muñoz
authors.forename: José
authors.initials: J
authors.lastname: Bagan
authors.forename: Rafael
authors.initials: R
authors.lastname: Poveda-Roda
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw; D017024:Chemotherapy, Adjuvant; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates